P42. Multiple neoplasms consist of lung cancer and hematological malignancies

Background: The lung cancer is a cancer of the most in Japan and first place in cause of death. Lung cancer still has poor prognosis with cure only in early clinical stage. Recently, new anti-cancer agent and molecular target agents are increased but clinical outcomes are not satisfied. We report that we reviewed 39 cases of multiple neoplasms with lung cancer and the hematological malignancies.

Methods: We intended for multiple neoplasms 298 cases including hematological malignancy. We reviewed 39 multiple neoplasms including the lung cancer. All patients were followed up until death or until December 2013. Survival was measured from the diagnosis of multiple cancer to time of death or last contact. Definition of the multiple neoplasms was in compliance with Warren & Gates. Also we determined the synchronous type and metachronous type in accordance with the definition of Moertel, so within less than 6 months was synchronous type, more than 6 months was metachronous type. About statistical examination, we used IBM SPSS statistics version 21.

Results: In total there are 39 cases, consisting of 30 males, nine females; type of multiple neoplasms: synchronous type 10 cases, metachronous type 29 cases. Number of multiple neoplasms: double neoplasms 20 cases, triple neoplasms 10 cases, quadruple neoplasms two cases. The median age was 70 years (range, 47-86 years). The counterpart of malignancies were: non-Hodgkin’s lymphoma 22 cases, myelodysplastic syndrome four cases, acute myelogeneous leukemia four cases, Hodgkin’s lymphoma two cases, macroglobulinemia one case, chronic lymphocytic leukemia two cases, chronic myelogeneous leukemia one case, acute lymphoblastic leukemia one case, monoclonal gammopathy of undetermined significance two cases. Other solid cancers were 14 cases. In double neoplasms, the median age of first diagnosis was 69 years and of the second cancer was 71 years. About interval between lung cancer and hematological malignancies, lung cancer precedence case was 34 M, hematological malignancy precedence case was 51 M. The median overall survival was 13 M.

Conclusions: Diagnosis of lung cancer within 5 years was made in eight cases out of 17 cases. The important point is that 5 years are required for careful observation at the time of hematological malignancy diagnosis. We think that the prognosis is improved.

Keywords: Lung cancer; hematological malignancy